Jazz Pharmaceuticals JAZZ Other comprehensive income/(loss) before reclassifications
Other comprehensive income/(loss) before reclassifications at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other comprehensive income/(loss) before reclassifications.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other comprehensive income/(loss) before reclassifications?
- Jazz Pharmaceuticals (JAZZ) reported other comprehensive income/(loss) before reclassifications of -$82.6M in Q1 2026.
- How has Jazz Pharmaceuticals's other comprehensive income/(loss) before reclassifications changed year-over-year?
- Jazz Pharmaceuticals's other comprehensive income/(loss) before reclassifications decreased by 150.8% year-over-year, from $162.45M to -$82.6M.
- What does other comprehensive income/(loss) before reclassifications mean?
- Total gains or losses recognized in equity that have not yet been moved into the income statement.
- How do you interpret other comprehensive income/(loss) before reclassifications?
- Positive values indicate unrealized gains in assets or favorable currency movements, while negative values reflect unrealized losses or unfavorable currency impacts.
- How does other comprehensive income/(loss) before reclassifications compare across companies?
- Standard reporting item for all public companies; highly dependent on global operations and investment portfolio performance.